Production of parvovirus B19 vaccine in insect cells co-infected with double baculoviruses

Parvovirus B19. Stellungnahmen des Arbeitskreises Blut des Bundesministeriums für Gesundheit

“…Versuche mit experimentellen Vakzinen weisen darauf hin, dass das Verhältnis der Proteinbausteine VP1 und VP2 einen wesentlichen Einfluss auf die Bildung neutralisierender Antikörper im Tierversuch hat. Ein Immunogen, das ≥25 % VP1 enthielt, induzierte neutralisierende Antikörper [82]. Erste klinische Prüfungen wurden unternommen und schienen erfolgversprechend [83].…”

“…Frühere Beiträge befassten sich mit der Creutzfeldt-Jakob-Erkrankung, dem Parvovirus B19 und dem GBVirus Typ C (HepatitisGVirus), (Bundesgesundheitsbl., 41,[78][79][80][81][82][83][84][85][86][87][88][89][90]1998), HTLV-I/-II, (Bundesgesundheitsbl., 41,512,1998), Yersinia enterocolitica, (Bundesgesundheitsbl., 42,613,1999), TT-Virus (Bundesgesundheitsbl., 43,[154][155][156]2000), Hepatitis B Virus (HBV (Bundesgesundheitsbl., 43,[240][241][242][243][244][245][246][247][248]2000 …”

Population kinetics during simultaneous infection of insect cells with two different recombinant baculoviruses for the production of rotavirus-like particles

“…Of these strategies, the use of individual baculoviruses allows the manipulation of the concentration of each protein by changing the multiplicity of infection (MOI) of each virus [3,5,6]. In this way, the stoichiometry between the structural proteins may be controlled.…”

“…In this way, the stoichiometry between the structural proteins may be controlled. In some VLP, which can have variable protein composition, changes in the ratio between structural proteins result in different VLP compositions, which can yield particles with different immunogenicity [5,6]. It is also possible that different stoichiometries between the structural proteins result in changes in VLP assembly efficiencies or kinetics, although this remains to be studied.…”

Parvovirus B19 and the New Century

“…Recently, several studies [21][22][23][24] (including a randomized, double-blind, phase 1 trial) have reported on a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1. All volunteers became parvovirus B19 seropositive after receiving at least 2 doses of vaccine.…”